PTC Therapeutics (NASDAQ:PTCT) Given New $53.00 Price Target

PTC Therapeutics (NASDAQ:PTCT – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $43.00 to $53.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on PTCT. Cantor Fitzgerald reissued […]

Related Keywords

Texas , United States , Jeromeb Zeldis , Raymond James , Matthewb Klein , Jpmorgan Chase Co , Jefferies Financial Group , Hexagon Capital Partners , Therapeutics Company Profile , Morgan Stanley , Therapeutics Inc , Allspring Global Investments Holdings , Cantor Fitzgerald , Goldman Sachs Group , Free Report , Get Free Report , Director Jerome , Capital Partners , Global Investments Holdings , Retirement System , Rhumbline Advisers ,